Myriad Genetics Signals Growth, Margin Expansion in 2026 Guidance
Event summary
- Myriad Genetics released preliminary Q4 2025 revenue of $207–$209 million and full-year revenue of $822–$824 million.
- The company projects full-year 2026 revenue between $860 million and $880 million, a ~6% increase year-over-year.
- Myriad anticipates adjusted EBITDA growth of approximately 43% to a range of $37–$49 million in 2026.
- The company is providing 2026 financial guidance without GAAP reconciliation due to the difficulty in predicting adjusting items.
The big picture
Myriad Genetics' preliminary results and 2026 guidance suggest a renewed focus on growth and margin expansion following a period of strategic realignment. The company's reliance on non-GAAP metrics for guidance highlights the complexity of forecasting its performance, particularly given the sensitivity to factors like litigation charges and acquisitions. This signals a need for investors to scrutinize the underlying drivers of these projections and assess the sustainability of the anticipated improvements.
What we're watching
- Execution Risk
- The company's ability to achieve its ambitious 2026 revenue and EBITDA targets will depend on successful product launches and efficient operational execution, particularly given the lack of GAAP reconciliation for guidance.
- Margin Sustainability
- Whether Myriad can sustain the projected adjusted gross margin of 68–69% will hinge on managing costs associated with new product launches and navigating potential pricing pressures within the diagnostics market.
- Regulatory Landscape
- Changes in reimbursement policies from governmental or private insurers could significantly impact Myriad's revenue projections and necessitate adjustments to its commercial strategy.
Related topics